RxDoctor Payments DataLook up a doctor →

Jennifer Dais, MD

Interventional Pain Medicine · Peoria, AZNPI 1982982591

Payments from drug & device makers

$30,124in general payments, 2019–2025

Across 573 payments — averaging $52.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nexxt Spine LLC$10K
  • Abbott$6K
  • Medtronic$3K
  • Boston Scientific$2K
  • Impactortho, Inc.$2K
  • Painteq LLC$1K
  • plus $6K from 37 others

What the payments were for

  • Royalty or licence$1,2044%
  • Consulting fees$6,43521%
  • Speaking & faculty fees$5692%
  • Travel & lodging$3,52112%
  • Food & beverage$16,66055%
  • Education$1,6355%
  • Entertainment$1010%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,124 in reported general payments places this provider in the 70th percentile of 64 interventional pain medicine providers in Arizona.

See all interventional pain medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$372,845
Medicare patients
237
Services billed
2,869

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl11$10,432
MovantikNaloxegol Oxalate11$9,877
Gabapentin340$4,492
Buprenorphine31$4,219
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen206$3,961
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen147$3,753
Pregabalin129$3,657
Duloxetine Hcl109$3,129
Oxycodone Hcl97$1,914
Morphine Sulfate66$1,872
Metaxalone14$1,233
Morphine Sulfate ErMorphine Sulfate57$1,113
Tramadol Hcl103$1,025
Lidocaine13$994
Baclofen50$875

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$165$10,43211 claims
Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate$42$6,09197 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 64 interventional pain medicine providers in Arizona.

Other interventional pain medicine in Peoria

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →